GlaxoSmithKline LLC et al v. Teva Pharmaceuticals USA Inc.

  1. July 11, 2024

    GSK Asks Judge To Rule In Teva IP Case, Citing Opioid Deals

    A GlaxoSmithKline lawyer has urged a Delaware federal judge to make up his mind about a nearly $400 million patent case against Teva Pharmaceuticals in light of unrelated "opioid-related cases" that the Israeli generic-drug maker has been settling in the billions of dollars.

  2. March 28, 2018

    Teva Skirts $235M Infringement Verdict In Coreg Patent Row

    A Delaware federal judge on Wednesday released Teva Pharmaceutical Industries Ltd. from a $235 million verdict over its generic version of GlaxoSmithKline LLC's heart medication Coreg, finding Teva did not infringe a patent covering the drug.

  3. October 26, 2017

    GSK, Teva See Bigger Issues Than Cash In $235M Award Fight

    Attorneys for GlaxoSmithKline and Teva Pharmaceuticals both told a Delaware federal judge on Thursday that far more than money is at stake in post-trial challenges to a $235 million heart drug infringement award won by GSK in June.

  4. August 28, 2017

    $235M Patent Award Spurs Teva Redo Request, GSK Fees Bid

    One month after a Delaware federal jury found Teva Pharmaceuticals willfully infringed a patent tied to the hypertension drug Coreg and handed GlaxoSmithKline a $235 million verdict, Teva on Friday pushed for the court to grant it judgment or a new trial, and GSK asked for enhanced damages and attorney fees.

  5. June 21, 2017

    GSK Wins $235M Verdict Against Teva In Coreg Patent Fight

    Teva Pharmaceuticals USA Inc. should pay GlaxoSmithKline LLC more than $235 million for willfully infringing a patent tied to the hypertension drug Coreg, a Delaware federal jury said.